Viridian Therapeutics, Inc. (VRDN)
Nasdaq: VRDN · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2013
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Feb 26, 2026 | Mar 3, 2025 | Feb 27, 2024 | Mar 9, 2023 | Mar 11, 2022 | Mar 26, 2021 | Mar 13, 2020 | Mar 14, 2019 | Mar 15, 2018 | Mar 24, 2017 |
| Revenue | 70,849 | 302 | 314 | 1,772 | 2,963 | 1,050 | 4,461 | 8,386 | 4,003 | 3,477r |
| Cost of revenue | · | · | · | · | · | · | · | · | · | 2,548 |
| Research and development | 338,929 | 238,254 | 159,765 | 100,894 | 56,886 | 28,304 | 34,794 | 30,421 | 19,623 | 13,692r |
| Selling, general and administrative | 95,315 | 61,083 | 94,999 | · | · | · | · | · | · | · |
| Sales and marketing | · | · | · | · | · | · | · | · | · | 1,669 |
| General and administrative | · | 61,083 | 94,999 | 35,182 | 25,805 | 13,265 | 11,646 | 11,049 | 10,912 | 6,772r |
| Total operating expenses | 434,244 | 299,337 | 254,764 | 136,076 | 82,691 | 111,430 | 46,440 | 41,470 | 30,535 | 20,464 |
| Total costs and expenses | · | · | · | · | · | · | · | · | · | 15,845 |
| Operating income | -363,395 | -299,035 | -254,450 | -134,304 | -79,728 | -110,380 | -41,979 | -33,084 | -26,532 | -16,987r |
| Interest expense | 4,948 | 2,197r | 1,331r | 486 | · | · | · | · | · | 95 |
| Interest and investment income | 27,399 | 31,597 | 18,240 | · | · | · | · | · | · | · |
| Total non-operating income (expense) | 20,794 | 29,086 | 16,716 | 4,430 | 315r | 173 | 941 | 1,254 | 403 | 39 |
| Income tax expense | 0 | · | · | · | · | · | · | · | · | · |
| Net income | -342,601 | -269,949 | -237,734 | -129,874 | -79,413 | -110,715 | -41,873 | -32,703 | -26,512 | -17,274r |
| Net income to common shareholders | · | · | · | · | -79,413 | -110,715 | -41,873 | -32,703 | -26,517 | -17,323 |
| Earnings per share, basic | · | · | -5.31 | -4.05 | -6.66 | -31.13 | · | · | · | · |
| Earnings per share, diluted | · | · | -5.31 | -4.05 | -6.66 | -31.13 | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | · | -31.13 | -20.04r | -1.10 | -1.38 | -28.21r |
| Weighted average shares, basic | · | · | 44,755,475 | 32,087,293 | 11,918,712 | 3,557,065 | · | · | · | · |
| Weighted average shares, diluted | · | · | 44,755,475 | 32,087,293 | 11,918,712 | 3,557,065 | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | · | 3,557,065 | 2,089,094r | 29,600,332 | 19,244,605 | 614,017r |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
us-gaap:SalesRevenueNetCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfRevenueResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseSales and marketing the cost of finding and serving customers
us-gaap:SellingAndMarketingExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:CostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted